Guardant Health Inc. is an American liquid biopsy company that develops blood tests for the early detection and monitoring of cancer. The technology enables non-invasive analysis of tumor DNA in blood, potentially replacing the need for invasive tissue biopsies. Guardant Health is included in the fund as diagnostic technologies improve the early detection of cancer, potentially significantly improving patient treatment outcomes.